Revenio Group Corporation: Revenio appointed Robin Pulkkinen as CFO

Revenio Group Corporation, Stock Exchange Release, June 3, 2015 at 16:30                               

Revenio appointed Robin Pulkkinen as CFO

Revenio Group Corporation has appointed M.Sc. Econ. Robin Pulkkinen (born 1980) as CFO and member of the management group as of July 15, 2015. Pulkkinen reports to the Revenio Group's President and CEO Olli-Pekka Salovaara.

Pulkkinen joins Revenio from the position of Symbio's EMEA area CFO. Prior to Symbio Pulkkinen has held several top management positions in international corporations both in Finland and Canada having solid experience in various roles of financial management.

"I am pleased to have Robin Pulkkinen joining us as the group CFO. Robin will bring us a wealth of international financial management view. His experience of the North American business culture is also very important to us, considering the significance of the US market to Revenio and health tech in general," states Olli-Pekka Salovaara.

Attachments: Robin Pulkkinen's CV and picture.

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis screening and monitoring. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology lies on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki. www.revenio.fi